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COST-EFFECTIVENESS OF ADJUVANT CHEMOTHERAPY
WITH URACIL-TEGAFUR,AN ORAL FLUOROPYRIMIDINE
DERIVATIVE, IN PATIENTS WITH NON-SMALL-CELL LUNG
CANCER IN JAPAN
Ikeda S1, Sakamaki H2,Yajima S2, Ikegami N2
1International University of Health and Welfare, Otawara-shi,Tochigi,
Japan, 2Keio University, Shinjuku-ku,Tokyo, Japan
OBJECTIVES: Uracil-tegafur (UFT), an oral anticancer agent, is
widely used to treat various types of cancer in many countries,
including Japan. The Japan Lung Cancer Research Group
(JLCRG) demonstrated that postoperative adjuvant chemother-
apy with UFT signiﬁcantly improves overall survival in patients
with stage I non-small-cell lung cancer, as compared with no
treatment after surgery (p = 0.04). Based on the results of the
JLCRG trial, we assessed the cost-effectiveness of UFT compared
to no treatment from a Japanese payer’s perspective.
METHODS: Data on individual patients of demographic char-
acteristics, clinical outcomes (survival) and medical resource use
including drug administration, consultations, treatment for
adverse events, post-relapse treatment were obtained from the
data base of the JLCRG trial. Medical costs were calculated
based on the Japanese national tariff. The incremental cost-
effectiveness ratio (ICER) of UFT in cost per life year gained over
a lifetime was estimated. Future costs and outcomes were dis-
counted at an annual rate of 3%. Sensitivity analyses were per-
formed on key parameters. RESULTS: A total of 979 patients
were included in the analysis. There were no signiﬁcant differ-
ences between the two groups in baseline characteristics. Total
medical costs from after surgery until death were $12,515 per
patient in the UFT group and $8522 per patient in the no treat-
ment group. The acquisition costs of UFT were $5464 per
patient. However, the costs of post-relapse treatment and
medical care up to the time of death were $937 and $686 lower
in the UFT group than in the no treatment group, respectively.
As compared with the no treatment group, the UFT group pro-
longed life by 0.74 years over a lifetime and ICER was $5367
per life year gained. This ﬁnding was not sensitive to plausible
variations in key parameters. CONCLUSIONS: Postoperative
adjuvant chemotherapy with UFT is cost-effective in patients
with non–small-cell lung cancer.
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ECONOMIC EVALUATION OF ANTIEMETIC REGIMENS FOR
PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA 
AND VOMITING
Mody RR1, Miller LA2, Higa G2, Scott V2, Madhavan SS2,Abraham J2
1TAP Pharmaceutical Products Inc, Lake Forest, IL, USA, 2West Virginia
University, Morgantown, WV, USA
OBJECTIVE: To evaluate the cost-effectiveness of antiemetic
regimens for prevention of chemotherapy-induced nausea and
vomiting. METHODS: A ﬁve-day decision model using efﬁcacy,
resource use and cost data from published sources, and expert
opinion was developed to determine the cost-effectiveness of four
antiemetic regimens: Regimen A) Aprepitant + Ondansetron +
Dexamethasone on day 1 and Aprepitant + Dexamethasone on
days 2 and 3 and only Dexamethasone on day 4; B) Ondansetron
+ Dexamethasone on day 1 and Dexamethasone on days 2–4;
C) Ondansetron + Dexamethasone on days 1–4; and D)
Ondansetron + Dexamethasone on day 1 and Dexamethasone +
Metoclopramide for days 2–4. A hypothetical cohort of 10,000
cancer patients scheduled to receive their ﬁrst cycle of single day,
outpatient, cisplatin-based highly emetogenic chemotherapy was
evaluated using Monte Carlo simulation. The primary outcome
measure was the cost per completely controlled patient (i.e., no
emesis and no use of rescue medications in both acute and
delayed phases). RESULTS: For regimens A, B, C, and D, the
expected costs from payer perspective were $593.45, $300.53,
$187.18, and $389.97, respectively. The expected costs from
societal perspective were $658.97, $431.56, $295.89 and
$494.84, respectively. Regimen A (67.6%) had highest expected
effectiveness followed by regimens C (55.5%), D (53.9%) and B
(47.8%). Regimens B and D were dominated by regimen C under
both perspectives. The incremental cost-effectiveness ratio
(ICER) per completely controlled patient for regimen A com-
pared to C was $3363.18 and $2881.61 from payer and societal
perspectives, respectively. The results were sensitive to the vari-
ations in the probability of no acute emesis and probability of
no delayed emesis given no acute emesis. CONLCUSIONS: This
study is among the ﬁrst to determine the cost-effectiveness of the
aprepitant-containing regimen compared to other combination
antiemetic regimens. The acceptability of regimen A as cost-
effective will depend on the acceptable threshold of ICER 
per completely controlled patient from the payer and societal
perspectives.
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COMBINATION IN THE TREATMENT OF ADVANCED BREAST
CANCER AFTER FAILURE OF ANTHRACYCLINE THERAPY
Davey P1,Arora BK2, Le Reun C1, Rajan N2, Liepa AM3, Pavlakis N4
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OBJECTIVE: To determine the cost-effectiveness of gemcitabine
plus paclitaxel (GT) therapy for patients with advanced breast
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cancer after failure of (neo) adjuvant anthracycline-based
therapy, relative to paclitaxel (T) monotherapy, in Australia.
Paclitaxel monotherapy is a treatment of choice in advanced,
anthracycline-resistant breast cancer in Australia. METHODS:
Economic evaluation was based on the global, randomised trial
of GT versus T (N = 529) (Albain et al, ASCO 2004). Median
survival for the intention-to-treat population was 18.5 months
(95% CI, 16.5 to 21.2 months) for the GT arm versus 15.8
months (95% CI, 14.4 to 17.4 months) for the T arm (hazard
ratio = 0.78 [95% CI, 0.63 to 0.96]. Higher toxicity in the com-
bination arm did not have a negative impact on quality of life
(Moinpour et al, ASCO 2004). Mean survival time for each
treatment arm was estimated from Kaplan-Meier survival curves.
Resource use (chemotherapy, administration, hospitalisation due
to adverse events [AEs], treatment emergent AEs) was applied as
per the trial and costed accordingly, using Australian dollars
(2004 value). Threshold of <$50,000 per life-year gained was
considered cost-effective. RESULTS: Mean cost per patient on
GT arm was $21,695 ($19,389 for chemotherapy, $1003 for
administration, and $1304 for AE management). Mean cost per
patient on T arm was $13,635 ($12,397 for chemotherapy, $567
for administration, and $670 for AE management). Mean sur-
vival gain for GT over T was 0.176 years. Cost per life-year
gained for GT was $45,799. CONCLUSION: This survival
beneﬁt is a highly patient-relevant outcome for advanced breast
cancer. This economic evaluation found that gemcitabine plus
paclitaxel offers an acceptable cost-effectiveness ratio and good
value-for-money for patients with advanced breast cancer in 
Australia.
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COST EFFECTIVENESS OF ADJUVANT, INTRAVESICAL
THERAPY FOR NON-INVASIVE TRANSITIONAL CELL
CARCINOMA OF THE BLADDER
Kerrigan M1, Ramsey SD2, Penson D3, Blough DK1, Garrison L1
1University of Washington, Seattle, WA, USA, 2Fred Hutchinson
Cancer Research Center, Seattle, WA, USA, 3University of Southern
California / Norris Cancer Center, Los Angeles, CA, USA
OBJECTIVES: Estimate the costs of care and outcomes associ-
ated with adjuvant, intravesical therapy (AIT)—either BCG or
chemotherapy—for non-invasive bladder cancer compared to no
AIT. METHODS: Subjects diagnosed with non-invasive transi-
tional cell carcinoma of the bladder between 1992 and 1999
were drawn from the SEER-Medicare dataset. We estimated the
effect of treatment on costs and outcomes within ﬁve risk groups
deﬁned by stage and grade of disease. We included subjects that
were at least 66 years old and who had fee-for-service coverage.
We estimated direct medical costs (for Medicare) using the
Kaplan-Meier sample average estimator. Using Cox models, we
estimated the effectiveness of AIT using three measures: survival
time, time to cystectomy (surgical removal of the bladder) and
time to repeat transurethral resection (TUR: surgical removal of
lesions in the bladder). The models adjusted for age, sex, race,
comorbidities and socioeconomic status. RESULTS: Subjects had
2 to 10 years of follow-up. A total of 13,658 subjects were
included: 2137 received AIT. Mean costs (2004 dollars) were
$53,834 for those that received AIT and $47,884 for those that
did not receive AIT. Difference in costs between treatment groups
was similar for the ﬁve risk groups. AIT reduced the risk of death
for subjects with stage 1, grade 3 or 4 tumors (hazard ratio: 0.82;
95% CI: 0.71 to 0.94). Survival was not statistically signiﬁcantly
different in other risk groups. AIT reduced the risk of repeat
TUR in each risk group. Conversely, AIT increased the risk of
cystectomy for subjects with low grade disease and carcinoma in
situ. CONCLUSIONS: AIT increased Medicare costs over 10
years by $5950. AIT reduced mortality for high risk subjects
only, reduced the risk of TUR for all risk groups and increased
the risk of cystectomy for low risk subjects. Residual confound-
ing may explain mixed ﬁndings.
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COST-EFFECTIVENESS ANALYSIS OF G-CSF IN ELDERLY
PATIENTS WITH AGGRESSIVE NON-HODGKIN’S LYMPHOMA
(NHL) RECEIVING CHOP
Lyman GH1, Cosler LE2
1University of Rochester School of Medicine and Dentistry, Rochester,
NY, USA, 2Albany College of Pharmacy, Albany, NY, USA
OBJECTIVES: A recent randomized trial compared granulocyte
colony-stimulating factor (G-CSF; ﬁlgrastim) to no G-CSF 
in elderly patients with aggressive NHL receiving CHOP
chemotherapy [Osby, 2003]. A cost-effectiveness analysis is pre-
sented comparing CHOP alone to CHOP + G-CSF. METHODS:
An economic model based on this trial compares the risk of neu-
tropenia, disease relapse, and 5-year survival among patients
receiving CHOP with or without G-CSF. Cost estimates were
derived from published literature and data from U.S. health
centers. Incremental cost-effectiveness ratios (ICERs) of $US/life
year saved (LYS) were estimated, and sensitivity analyses per-
formed. RESULTS: CHOP + G-CSF was associated with signif-
icantly fewer episodes of severe neutropenia (P < 0.001), FN (P
< 0.001), greater dose intensity (P < 0.05), fewer deaths (P =
0.04), and improved 5-year survival (P = 0.04). Based on ﬁve
years of followup, the life years averaged 2.93 years in the CHOP
alone group compared to 3.52 years in the CHOP + G-CSF arm.
Expected costs were $41,400 and $39,747 for the G-CSF and
control arms, respectively. Under baseline assumptions, the ICER
for G-CSF support was estimated at $2769/LYS. Sensitivity
analyses revealed G-CSF support to be cost saving across most
plausible values for baseline FN risk, relative risk reductions for
FN, infection-related mortality, and risks of disease relapse. G-
CSF support remained cost saving until the control risk for
disease relapse fell to <2%. Net cost savings were observed for
FN relative risk reductions >56%. CONCLUSIONS: A recent
clinical trial of G-CSF support demonstrated a reduction in neu-
tropenic complications and improved survival. Incorporation of
cost data into an economic model based on this trial demon-
strates that G-CSF support is within accepted limits for cost-
effectiveness across a broad range of assumptions.
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COST-EFFECTIVENESS ANALYSIS OF APREPITANT IN THE
PREVENTION OF CHEMOTHERAPY-INDUCED NAUSEA AND
VOMITING IN PATIENTS RECEIVING EITHER CISPLATIN-
BASED CHEMOTHERAPY REGIMENS OR MODERATELY
EMETOGENIC CHEMOTHERAPY
Annemans L1, Strens D1, Lox E2, Petit C2, Malonne H2
1HEDM-IMS Health, Brussels, Belgium, 2Merck Sharp & Dohme bv,
Brussels, Belgium
OBJECTIVES: Aprepitant is effective in preventing 
chemotherapy-induced nausea and vomiting (CINV), achieving
higher complete response (CR = no emesis and no rescue
therapy) compared to standard prevention, in patients receiving
either highly (HEC) or moderately emetogenic chemotherapy
(MEC) (absolute improvement = 11% and 13% respectively).
We assessed the cost-effectiveness of aprepitant based versus
standard prevention in these indications in Belgium.
METHODS: A decision analytical model was developed in MS
Excel. To estimate resource use, two approaches are used. The
ﬁrst is based on the preventive regimens applied in randomized
controlled trials comparing aprepitant based CINV prevention
